Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Licenses Scorpions Technology from DxS

NEW YORK, July 20 (GenomeWeb News) - Cepheid has licensed a probe technology for real-time PCR from DxS, the company said today.

 

Under the agreement, Cepheid may use DxS' Scorpions technology for all markets except clinical diagnostics, wine production, and the detection of chemicals used in agriculture. Scorpions probes contain a PCR primer covalently linked to a fluorescent probe.

 

Cepheid plans to use the technology for food, agriculture, and environmental testing, starting with recreational water testing, combining it with its own SmartCycler and GeneXpert systems.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.